Von Eschenbach’s Commissioner Debut May Be Release Of Safety Report
Executive Summary
One of Andrew von Eschenbach's first major steps as FDA commissioner is likely to be release of the agency task force response to the Institute of Medicine's recommendations to improve drug safety oversight
You may also be interested in...
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Former deputy commissioner will also likely push increased use of biomarkers and more flexibility in off-label communication, among other reforms.
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Former deputy commissioner will also likely push increased use of biomarkers and more flexibility in off-label communication, among other reforms.
Sen. Baucus “Expects Answers” On Sen. Grassley’s FDA Inquiries
The inquiries by Senate Finance Committee Ranking Minority Member Chuck Grassley, R-Iowa, into FDA carry the imprimatur of committee chairman Max Baucus, D-Mont., even though the two senators traded leadership positions with the start of the 110 Congress, Baucus says